A non-randomized, open-label, dose-finding, first-in-human, trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection. (Updated June 2, 2023).
In: Cancer Gene Therapy Week, 2023-06-19, S. 2-2
serialPeriodical
Zugriff:
Titel: |
A non-randomized, open-label, dose-finding, first-in-human, trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection. (Updated June 2, 2023).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2023-06-19, S. 2-2 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|